MedTrace Logo

Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients

NCT06015061 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-08-29

No results posted yet for this study

Summary

Anlotinib is a multi-target receptor tyrosine kinase inhibitor (TKI) targeting tumor angiogenesis and growth. The purpose of this study is to evaluate the efficiency of contrast enhanced ultrasound in assessing effectiveness of anlotinib in patients with locally advanced, metastatic, or unresectable pheochromocytoma or paraganglioma(PPGL).

Conditions

  • Pheochromocytoma, Metastatic
  • Ultrasonography
  • Paraganglioma, Malignant
  • Pheochromocytoma Malignant

Interventions

DIAGNOSTIC_TEST

Contrast-enhanced ultrasound(CEUS)

CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in PPGL tumors.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Anli Tong · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2025-03-01
Completion
2025-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06015061 on ClinicalTrials.gov